Published by Alexis Pellek on January 22, 2009
under Biotech
Key results from a colon cancer study of Genentech’s Avastin (bevacizumab) could be available in April, according to a Securities and Exchange Commission filing. Genentech previously said results would be available mid-year. The drug is currently approved to treat breast and lung cancer, and it’s a first- and second-line treatment for metastatic colorectal cancer. Read more »
Published by Alexis Pellek on January 15, 2009
under Biotech, R&D
Last month, the International AIDS Vaccine Initiative (IAVI) and the Rockefeller Foundation announced a challenge to HIV/AIDS scientists: design an AIDS-fighting protein to win $150,000. The winning protein design and sample will advance HIV vaccine development, and the winning researchers could receive a bonus of up to $1 million and/or the chance to pursue their research further with help from IAVI. Read more »
Published by Maribel Rios on December 9, 2008
under Manufacturing, Trends
Innovation used to be a term dedicated to a company’s visions for growth. Keeping one eye on the roots of your business and the other on long-term prospects was a smart strategy. Against a backdrop of a nose-diving economy, however, it seems as if “innovation” now has less to do with growth and more to do with survival. Read more »
Published by Alexis Pellek on September 26, 2008
under Asia News, Biotech, Europe News, Manufacturing, North America News, Trends
Last week’s post highlighted pharma deals that haven’t been working out due to rejected bids and stalled negotiations. On a more positive note, the past several months have also seen some successful acquisitions. This past week produced updates to some of Big Pharma’s pending pacts. Read more »
Published by Alexis Pellek on September 19, 2008
under Asia News, Biotech, Europe News, Manufacturing, North America News, Trends
The past several months have seen many successful merger and acquisition announcements come and go, but for some companies, this has hardly been a summer of love. Several of Big Pharma’s big offers have been rejected, and some of these stories are still playing out. Only time will tell what the future holds for these proposed deals and sometimes troubled partnerships. Read more »
Published by Alexis Pellek on July 17, 2008
under R&D
When I was in school, HIV/AIDS education was part of the health curriculum. I sat with my middle-, and then, high-school classmates and we learned about AIDS prevention, wore red ribbons, watched the made-for-TV movie The Ryan White Story, and attended school-wide AIDS awareness presentations by people living with HIV. All the time knowing scientists were hard at work finding a cure. Read more »
« Previous Page